文献速递其他结缔组织病

幼年特发性炎症性肌病:近五十年分类、发病机制与治疗进展

Juvenile Myositis: Insights on Classification, Pathogenesis, and Therapies Over the Past 50 Years.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2026-09-09

本文综述了幼年特发性炎症性肌病(JIIM)过去50年在分类、发病机制和治疗方面的进展。JIIM是罕见、严重的多系统自身免疫病,50年前预后差、治疗选择极少;随着肌炎研究社区的国际合作与肌炎自身抗体与表型关联的识别,分类不断细化,JDM仍最常见但高度异质,现代治疗路径显著改善了患儿结局。

要点

  • JIIM是罕见严重的儿童多系统自身免疫病,50年前预后差且治疗有限。
  • 肌炎自身抗体与特定表型的关联推动了JIIM分类的细化。
  • 国际合作与发病机制研究促进了现代治疗路径发展并改善结局。

核心结论

  • 过去50年对JIIM分类、发病机制和治疗的理解显著增长,现代治疗路径已大幅改变并改善了患儿结局。

研究设计与样本

  • 本文为综述,总结近50年幼年特发性炎症性肌病在分类、发病机制与治疗方面的研究进展。

主要发现

  • 早期认为幼年皮肌炎(JDM)基本是一种疾病,现代认识显示JIIM存在不同类型且JDM本身高度异质。
  • 肌炎自身抗体与特定表型的关联部分驱动了JIIM分类的发展。
  • 肌炎研究社区的国际合作与JIIM专项研究增长促进了领域进展。

临床怎么用

  • 临床应认识到JIIM包含不同亚型且JDM高度异质,并关注肌炎自身抗体与表型的关联以辅助分类。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The juvenile idiopathic inflammatory myopathies (JIIMs) are rare, serious, multisystem autoimmune diseases affecting children and young people. Fifty years ago, the prognosis for these conditions was poor, with high morbidity and mortality, and very few treatments were available. Since then, there has been major growth in our understanding of the pathogenesis and evidence basis for treatment. Early descriptions considered juvenile dermatomyositis (JDM) to be essentially one disease. Our modern understanding has shown that there are different types of JIIMs, and that although JDM remains the most prevalent, even JDM itself is highly heterogenous. Much progress has been made possible through concomitant growth in the research community with a focus on JIIMs and the fact that the myositis research and clinical communities are highly collaborative internationally. Here, we review the growing understanding of the different types of childhood myositis; the developments in classification, driven in part by recognition of associations of particular phenotypes with specific myositis autoantibodies; the novel insights into pathogenesis of the JIIMs; the therapeutic targets that these have revealed; and the evidence for, and development of, modern treatment care pathways, which have changed radically in recent decades. This has resulted in improved outcomes for children and young people with JIIMs and hope for further groundbreaking developments.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Wedderburn LR, Feldman BM, Rider LG, et al. Juvenile Myositis: Insights on Classification, Pathogenesis, and Therapies Over the Past 50 Years. Arthritis Care Res (Hoboken). 2026. PMID: 42439320. doi:10.1002/acr.80115

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。